| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2020: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
Bone metastases are common in advanced cancers, resulting in clinically important complications. The effectiveness of zoledronic acid (ZA) and denosumab in the treatment of bone metastases has been established. Despite the effectiveness of these agents, these medications often cause severe adverse events (AEs) such as medication-related osteonecrosis of the jaw (MRONJ). Accumulating the information on risk factors of AEs are useful to manage them. Therefore, we conducted researches to evaluated risk factors developing MRONJ in patients who treatment with denosumab or ZA.
In addition, we investigated the risk factors of AEs associated with chemotherapy in patients with advanced cancer. We also developed a protocol-based pharmacotherapy management to aid the administration of immunotherapy to patients with lung cancer.
The results from our researches provide information for safe and sustainable medication therapy for patients with advanced cancer.
|
